Our team has unmatched expertise in fibrosis biology and is focused on discovering and developing novel targeted therapies to address life-threatening fibrotic diseases. Our research in a variety of forums is regularly published and presented at medical and scientific conferences.
Advancing Discoveries in Fibrosis
Papers
- Dual inhibition of αvβ6 and αvβ1 reduces fibrogenesis in lung tissue explants from patients with IPF →
- TGF-β as a driver of fibrosis: physiological roles and therapeutic opportunities →
- Dual antagonists of α5β1/αvβ1 integrin for airway hyperresponsiveness →
- Insights into Protein-Ligand Interactions in Integrin Complexes: Advances in Structure Determinations →
- The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis →
- The αvβ1 integrin plays a critical in vivo role in tissue fibrosis →
- Targeting of αv integrin identifies a core molecular pathway that regulates fibrosis in several organs →
- Epithelial-mesenchymal interactions in fibrosis and repair. Transforming growth factor-β activation by epithelial cells and fibroblasts →
- Evaluation of integrin αvβ 6 cystine knot PET tracers to detect cancer and idiopathic pulmonary fibrosis →
- Integrin alphavbeta6 is a marker of the progression of biliary and portal liver fibrosis and a novel target for antifibrotic therapies →
Posters & Presentations
Posters
- Profiling fibrosis regression in a rat model of non-alcoholic steatohepatitis →
- PK/PD assessment of an oral, selective αVβ6 /αVβ1 integrin dual antagonist, PLN-74809, for the treatment of idiopathic pulmonary fibrosis →
- Dual αVβ6 /αVβ1 inhibitor PLN-74809 blocks multiple TGF-β activation pathways associated with IPF →
- PLN-74809, a dual αVβ6/αVβ1 integrin inhibitor, inhibits fibrosis in precision-cut liver tissue from PSC and PBC patients and the Mdr2 knockout mouse →
- PLN-74809, a dual αvβ6/αvβ1, oral, selective integrin inhibitor, is well tolerated and reduces lung TGF-β activity in healthy volunteers →